Accrual Suspensions in Seamless Phase II/III Trials: A Review of NRG Oncology Trials
Chen Hu, Boris Freidlin, Edward L Korn · 2024
Read Accrual Suspensions in Seamless Phase II/III Trials: A Review of NRG Oncology Trials by Chen Hu, Boris Freidlin, Edward L Korn (2024) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11698020.txt.
Description
Chen Hu, Boris Freidlin, and Edward L Korn reviewed cancer trials that pause enrollment midway to decide whether a treatment deserves a full large test, in a paper published in 2024. These combined phase II and III trials can spare patients from weak treatments, but the pause can drag on while early data ripen.
The authors gathered twenty-two such trials run by a national cancer network and its forerunner groups. Most planned a pause, and every finished trial's pause ran longer than planned, by three to twenty months. They discuss a calendar backstop: a fixed date by which the go or no-go call is made with whatever data exist. One trial is used to show the trade-offs plainly.
Catalog record
| CREATOR | Chen Hu, Boris Freidlin, Edward L Korn |
|---|---|
| YEAR | 2024 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 18 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |